Prelude Therapeutics Incorporated
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRLD research report →
Companywww.preludetx.com
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors.
- CEO
- Krishna Vaddi
- IPO
- 2020
- Employees
- 131
- HQ
- Wilmington, DE, US
Price Chart
Valuation
- Market Cap
- $246.59M
- P/E
- -4.69
- P/S
- 10.70
- P/B
- 6.07
- EV/EBITDA
- -2.12
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 97.66%
- Op Margin
- -503.21%
- Net Margin
- -465.30%
- ROE
- -118.24%
- ROIC
- -104.28%
Growth & Income
- Revenue
- $12.14M · 73.43%
- Net Income
- $-99,498,000 · 21.76%
- EPS
- $-1.29 · 23.21%
- Op Income
- $-104,566,000
- FCF YoY
- 45.62%
Performance & Tape
- 52W High
- $5.54
- 52W Low
- $0.75
- 50D MA
- $4.10
- 200D MA
- $2.33
- Beta
- 1.10
- Avg Volume
- 397.01K
Get TickerSpark's AI analysis on PRLD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Morris Charles Q | other | 450,000 |
| Apr 27, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 1,407,000 |
| Apr 27, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 1,407,000 |
| Apr 21, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 0 |
| Apr 21, 26 | Bonita David P | buy | 1,689,189 |
| Apr 21, 26 | Bonita David P | buy | 1,126,126 |
| Apr 21, 26 | ORBIMED ADVISORS LLC | buy | 1,689,189 |
| Apr 21, 26 | ORBIMED ADVISORS LLC | buy | 1,126,126 |
| Apr 21, 26 | BAKER BROS. ADVISORS LP | buy | 2,137,651 |
| Apr 21, 26 | BAKER BROS. ADVISORS LP | buy | 114,601 |
Our PRLD Coverage
We haven't published any research on PRLD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PRLD Report →